DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer

DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate

Syngene reports revenue from operations up 8% in Q1 FY 23

Company raises the annual revenue guidance from mid-teens to high teens

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Healthcare Startup Shri Chyawan Ayurved raises USD 200k in SEED round

The funds raised in the seed round will be used for research and development of Shri Chyawan Ayurved Product

Roche's Elecsys Amyloid Plasma Panel granted FDA breakthrough device designation to enable a timely diagnosis of Alzheimer’s disease

The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.

Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.

Essential Pharma progress in its ESG performance

The company now exceeds the sector benchmark for its overall ESG rating and for all three measures

GSK’s Haleon begins trading in LSE

Completion of the demerger of Haleon and share consolidation of GSK

Orchid Pharma updates on PLI scheme benefits for its subsidiary

The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"

Sumitomo Pharma Oncology receives Orphan Drug Designation for DSP-0390 for the treatment of brain cancer

The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people